Treats attention deficit hyperactivity disorder (ADHD). ANDA 76772, held by Actavis Laboratories FL. Methylphenidate Hydrochloride.
As of Nov 21, 2026, ANDA 76772 (Methylphenidate Hydrochloride), held by Actavis Laboratories FL, was first approved by FDA on Mar 22, 2018, with 0 approved supplements and 0 published complete response letters.
Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 6 to 65 years old. Limitations of Use The use of methylphenidate hydrochloride extended-release tablets are not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 22, 2018 | Original application | Approved | None posted |
| Methylphenidate Hydrochloride18MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride27MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride36MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | Rx |
| Methylphenidate Hydrochloride54MG ยท tablet, extended release;oral | Methylphenidate Hydrochloride | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters